Literature DB >> 8690449

Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.

C Hale1, M Bartholomew, V Taylor, J Stables, P Topley, J Tite.   

Abstract

Cloning of the CD52 from a B-lymphocyte tumour cDNA library revealed two closely related sequences differing only at two amino acids C-terminal to the proposed point of glycosylphosphatidylinositol (GPI)-linkage. When transfected into CHO cells only one of these sequences gave high-level expression of the antigen recognized by the prototypic anti-CD52 antibody CAMPATH-1 whereas in JURKAT cells good expression levels were obtained with both sequences. Fusion of the sequence from the second sequence to DNA encoding the extracellular domain of CD4 indicated that this sequence was capable of directing GPI linkage. The possible implications for the function of CD52 and serotherapy with anti-CD52 antibodies are discussed.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8690449      PMCID： PMC1456427          DOI： 10.1111/j.1365-2567.1996.tb00003.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


  13 in total

1.  CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation.

Authors:  M Deckert; J Kubar; A Bernard
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

2.  Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone.

Authors:  M Q Xia; M Tone; L Packman; G Hale; H Waldmann
Journal:  Eur J Immunol       Date:  1991-07       Impact factor: 5.532

3.  The CAMPATH-1 antigen (CDw52).

Authors:  G Hale; M Q Xia; H P Tighe; M J Dyer; H Waldmann
Journal:  Tissue Antigens       Date:  1990-03

4.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

Authors:  M Q Xia; G Hale; M R Lifely; M A Ferguson; D Campbell; L Packman; H Waldmann
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

5.  Humanised monoclonal antibody therapy for rheumatoid arthritis.

Authors:  J D Isaacs; R A Watts; B L Hazleman; G Hale; M T Keogan; S P Cobbold; H Waldmann
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

6.  Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1.

Authors:  A M Shenoy-Scaria; J Kwong; T Fujita; M W Olszowy; A S Shaw; D M Lublin
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

7.  Primary structure of CD52.

Authors:  A Treumann; M R Lifely; P Schneider; M A Ferguson
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

8.  A major mRNA of the human epididymal principal cells, HE5, encodes the leucocyte differentiation CDw52 antigen peptide backbone.

Authors:  C Kirchhoff; N Krull; I Pera; R Ivell
Journal:  Mol Reprod Dev       Date:  1993-01       Impact factor: 2.609

9.  Fusion of sequence elements from non-anchored proteins to generate a fully functional signal for glycophosphatidylinositol membrane anchor attachment.

Authors:  P Moran; I W Caras
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307
View more
  10 in total

1.  Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.

Authors:  Simonetta Galgani; Luca Prosperini; Shalom Haggiag; Carla Tortorella; Claudio Gasperini
Journal:  J Neurol       Date:  2018-07-17       Impact factor: 4.849

2.  Establishment a CHO Cell Line Expressing Human CD52 Molecule.

Authors:  Kadijeh Tati; Mahsa Yazdanpanah-Samani; Amin Ramezani; Elham Mahmoudi Maymand; Abbas Ghaderi
Journal:  Rep Biochem Mol Biol       Date:  2016-10

3.  Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.

Authors:  W Rowan; J Tite; P Topley; S J Brett
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

4.  Alemtuzumab depletion failure can occur in multiple sclerosis.

Authors:  Nicolas Dubuisson; David Baker; Angray S Kang; Gareth Pryce; Monica Marta; Leo H Visser; Werner E Hofmann; Sharmilee Gnanapavan; Gavin Giovannoni; Klaus Schmierer
Journal:  Immunology       Date:  2018-01-04       Impact factor: 7.397

5.  Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

Authors:  Sambasiva P Rao; Jose Sancho; Juanita Campos-Rivera; Paula M Boutin; Peter B Severy; Timothy Weeden; Srinivas Shankara; Bruce L Roberts; Johanne M Kaplan
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

6.  CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function.

Authors:  Kartik Bhamidipati; John L Silberstein; Yashaar Chaichian; Matthew C Baker; Tobias V Lanz; Amin Zia; Yusuf S Rasheed; Jennifer R Cochran; William H Robinson
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

7.  Screening and Identification of Key Microenvironment-Related Genes in Non-functioning Pituitary Adenoma.

Authors:  Jing Guo; Qiuyue Fang; Yulou Liu; Weiyan Xie; Chuzhong Li; Yazhuo Zhang
Journal:  Front Genet       Date:  2021-04-27       Impact factor: 4.599

Review 8.  Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.

Authors:  Nik Krajnc; Gabriel Bsteh; Thomas Berger; Jan Mares; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2022-04-04       Impact factor: 6.088

9.  Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.

Authors:  Z Li; S Richards; H K Surks; A Jacobs; M A Panzara
Journal:  Clin Exp Immunol       Date:  2018-10-01       Impact factor: 4.330

10.  A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.

Authors:  Liaqat Ali; Gauri Saxena; Meleri Jones; Georgia R Leisegang; Luke Gammon; Sharmilee Gnanapavan; Gavin Giovannoni; Klaus Schmierer; David Baker; Angray S Kang
Journal:  Biotechniques       Date:  2020-02-25       Impact factor: 1.993
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.